Incyte earns $19M milestone from Lilly

Wilmington, DE-based Incyte says that it earned a rich $19 million milestone from Eli Lilly after the pharma company launched the Phase IIb study of the rheumatoid arthritis drug INCB28050. Lilly inked a licensing pact covering Incyte's oral JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104. Incyte release